Tangney Jeffrey 4
4 · Doximity, Inc. · Filed Jul 24, 2026
Research Summary
AI-generated summary of this filing
Doximity (DOCS) CEO Jeffrey Tangney Receives 2.48M Stock Option Grant
What Happened Jeffrey Tangney, CEO of Doximity (DOCS), was granted a derivative award on July 22, 2026 for 2,480,000 shares at $0.00 per share (reported as an "A" — award/grant). This is a stock option-style grant (no cash paid) that will only vest and become exercisable if specified performance and service conditions are met.
Key Details
- Transaction date: July 22, 2026; Form 4 filed July 24, 2026 (appears timely).
- Grant: 2,480,000 shares, acquisition price $0.00 (derivative award).
- Vesting: Four equal annual installments beginning July 22, 2027, contingent on the daily closing price of DOCS being ≥ $28.02 for any 60 consecutive trading days during July 22, 2026–July 22, 2030, and the Reporting Person's continuous service through each vesting date (per footnote).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Transaction type: Award/grant (not a cash purchase, sale, or option exercise).
Context This filing records a performance- and service-based option grant — it does not represent an immediate purchase or sale of shares. Value will be realized only if the performance threshold and service conditions are satisfied and the options are later exercised. Such grants are commonly used for executive compensation and do not, by themselves, indicate near-term buying or selling by the insider.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-07-22+2,480,000→ 2,480,000 totalExercise: $28.02Exp: 2036-07-22→ Class A Common Stock (2,480,000 underlying)
Footnotes (1)
- [F1]The stock option vests and becomes exercisable, if at all, in four equal annual installments beginning on July 22, 2027, if the daily closing price of the Issuer's Class A Common Stock on the New York Stock Exchange equals or exceeds $28.02 per share during any 60 consecutive trading day period from July 22, 2026 to July 22, 2030, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The stock option was granted on July 22, 2026.